Stock Earnings
Understanding the Risks of Investing in Outlook Therapeutics Inc (OTLK)
Outlook Therapeutics Inc’s filing revealed that its Director Haddadin Yezan Munther acquired Company’s shares for reported $22242.0 on Mar 28
Menu
Outlook Therapeutics Inc’s filing revealed that its Director Haddadin Yezan Munther acquired Company’s shares for reported $22242.0 on Mar 28